GRF Stock Overview
Operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally.
Snowflake Score | |
---|---|
Valuation | 3/6 |
Future Growth | 4/6 |
Past Performance | 3/6 |
Financial Health | 2/6 |
Dividends | 0/6 |
Rewards
Risk Analysis
Grifols, S.A. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | €9.21 |
52 Week High | €15.92 |
52 Week Low | €6.36 |
Beta | 0.67 |
11 Month Change | 17.23% |
3 Month Change | 9.04% |
1 Year Change | -29.88% |
33 Year Change | -57.02% |
5 Year Change | -68.14% |
Change since IPO | 251.01% |
Recent News & Updates
Recent updates
Grifols (BME:GRF) Posted Healthy Earnings But There Are Some Other Factors To Be Aware Of
May 21Are Investors Undervaluing Grifols, S.A. (BME:GRF) By 32%?
Apr 20Grifols, S.A. Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now
Mar 04Revenues Working Against Grifols, S.A.'s (BME:GRF) Share Price Following 27% Dive
Mar 01Does Grifols (BME:GRF) Have A Healthy Balance Sheet?
Feb 20Benign Growth For Grifols, S.A. (BME:GRF) Underpins Its Share Price
Jan 09Here's Why Grifols (BME:GRF) Is Weighed Down By Its Debt Load
Nov 10Is Grifols, S.A. (BME:GRF) Expensive For A Reason? A Look At Its Intrinsic Value
Oct 20Is Grifols (BME:GRF) A Risky Investment?
Aug 03Calculating The Fair Value Of Grifols, S.A. (BME:GRF)
May 18Shareholder Returns
GRF | ES Biotechs | ES Market | |
---|---|---|---|
7D | -0.2% | 0.2% | 0.7% |
1Y | -29.9% | -26.2% | 13.2% |
Return vs Industry: GRF underperformed the Spanish Biotechs industry which returned -26.2% over the past year.
Return vs Market: GRF underperformed the Spanish Market which returned 13.2% over the past year.
Price Volatility
GRF volatility | |
---|---|
GRF Average Weekly Movement | 7.3% |
Biotechs Industry Average Movement | 7.4% |
Market Average Movement | 3.0% |
10% most volatile stocks in ES Market | 6.0% |
10% least volatile stocks in ES Market | 0.6% |
Stable Share Price: GRF has not had significant price volatility in the past 3 months.
Volatility Over Time: GRF's weekly volatility (7%) has been stable over the past year, but is still higher than 75% of Spanish stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1909 | 23,000 | Nacho Abia Buenache | www.grifols.com |
Grifols, S.A. operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand's disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer’s disease. It markets diagnostic testing equipment, reagents, and other equipment; biological products; manufactures and sells plasma to third parties; and involves in research activities, as well as markets pharmaceutical products for hospital pharmacies.
Grifols, S.A. Fundamentals Summary
GRF fundamental statistics | |
---|---|
Market cap | €5.75b |
Earnings (TTM) | €189.00m |
Revenue (TTM) | €6.66b |
33.1x
P/E Ratio0.9x
P/S RatioIs GRF overvalued?
See Fair Value and valuation analysisEarnings & Revenue
GRF income statement (TTM) | |
---|---|
Revenue | €6.66b |
Cost of Revenue | €4.09b |
Gross Profit | €2.56b |
Other Expenses | €2.37b |
Earnings | €189.00m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Jul 30, 2024
Earnings per share (EPS) | 0.28 |
Gross Margin | 38.51% |
Net Profit Margin | 2.84% |
Debt/Equity Ratio | 140.3% |
How did GRF perform over the long term?
See historical performance and comparison